Inhibition of GPX4 with the compound RSL3 has been shown to selectively reduce the population of persistent cancer cells in various cancer cell lines, including breast (BT474), melanoma (A375), ovarian (Kuramochi), and lung (PC9), and as well as in A375 melanoma xenograft models (196). Here, GPX4 is linked to melanoma.